Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2021 - 2025)

Kiniksa Pharmaceuticals International's Short-term Investments history spans 5 years, with the latest figure at $248.5 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 313.81% year-over-year to $248.5 million; the TTM value through Dec 2025 reached $248.5 million, up 313.81%, while the annual FY2025 figure was $248.5 million, 313.81% up from the prior year.
  • Short-term Investments reached $248.5 million in Q4 2025 per KNSA's latest filing, up from $177.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $248.5 million in Q4 2025 to a low of $210000.0 in Q1 2021.
  • Average Short-term Investments over 5 years is $84.1 million, with a median of $77.4 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: surged 39068.1% in 2022, then plummeted 38.99% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $59.7 million in 2021, then increased by 13.66% to $67.9 million in 2022, then skyrocketed by 44.96% to $98.4 million in 2023, then plummeted by 38.99% to $60.0 million in 2024, then surged by 313.81% to $248.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Short-term Investments are $248.5 million (Q4 2025), $177.2 million (Q3 2025), and $115.7 million (Q2 2025).